Revvity (NYSE:RVTY – Get Free Report) had its price objective upped by JPMorgan Chase & Co. from $160.00 to $165.00 in a note issued to investors on Monday, Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 10.37% from the company’s current price.
Several other brokerages have also issued reports on RVTY. Cfra raised Revvity from a “hold” rating to a “buy” rating in a research report on Wednesday, November 4th. UBS Group initiated coverage on Revvity in a research report on Wednesday, September 9th. They set a “neutral” rating and a $140.00 price target on the stock. Zacks Research raised shares of Revvity from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Sanford C. Bernstein reissued a “market perform” rating on shares of Revvity in a research note on Thursday. Finally, Weiss Ratings raised shares of Revvity from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday. Six analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. Based on data from MarketBeat, Revvity presently has a consensus rating of “Hold” and an average target price of $134.21.
Get Our Latest Report on Revvity
Revvity Trading Down 3.2%
Shares of RVTY stock traded down $4.89 during mid-day trading on Monday, reaching $149.50. The stock had a trading volume of 564,370 shares, compared to its average volume of 1,537,487. Revvity has a 52-week low of $81.22 and a 52-week high of $171.74. The firm has a market capitalization of $16.69 billion, a PE ratio of 66.31, a price-to-earnings-growth ratio of 2.70 and a beta of 1.08. The company has a current ratio of 2.65, a quick ratio of 2.10 and a debt-to-equity ratio of 0.36. The stock’s 50-day moving average price is $150.48 and its two-hundred day moving average price is $114.30.
Revvity (NYSE:RVTY – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported $1.38 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.08. The business had revenue of $728.90 million during the quarter, compared to analyst estimates of $694.73 million. Revvity had a return on equity of 8.64% and a net margin of 8.61%. Revvity’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.18 EPS. Equities analysts expect that Revvity will post 5.42 earnings per share for the current fiscal year.
Insider Activity
In related news, insider Tajinder S. Vohra sold 7,330 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total value of $1,032,650.40. Following the transaction, the insider owned 6,635 shares of the company’s stock, valued at approximately $934,738.80. This trade represents a 52.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Maxwell Krakowiak sold 1,631 shares of the business’s stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $144.53, for a total transaction of $235,728.43. Following the sale, the insider owned 14,781 shares of the company’s stock, valued at $2,136,297.93. This trade represents a 9.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 9,045 shares of company stock valued at $1,281,439 in the last ninety days. Insiders own 0.85% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the business. Apollon Wealth Management LLC boosted its stake in shares of Revvity by 2.7% during the third quarter. Apollon Wealth Management LLC now owns 2,778 shares of the company’s stock valued at $425,000 after purchasing an additional 73 shares in the last quarter. Moors & Cabot Inc. increased its holdings in Revvity by 3.1% during the third quarter. Moors & Cabot Inc. now owns 2,448 shares of the company’s stock valued at $374,000 after buying an additional 73 shares during the period. Northwestern Mutual Wealth Management Co. raised its stake in Revvity by 5.4% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,074 shares of the company’s stock worth $231,000 after buying an additional 106 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in Revvity by 17.0% in the first quarter. EverSource Wealth Advisors LLC now owns 749 shares of the company’s stock worth $66,000 after buying an additional 109 shares in the last quarter. Finally, Angeles Wealth Management LLC raised its stake in Revvity by 2.0% in the second quarter. Angeles Wealth Management LLC now owns 5,804 shares of the company’s stock worth $646,000 after buying an additional 112 shares in the last quarter. 86.65% of the stock is currently owned by institutional investors.
About Revvity
Revvity, Inc. develops and supplies products and services for life sciences research and clinical diagnostics. Its offerings include instruments, reagents, software and related services used by pharmaceutical and biotechnology companies, academic and government research institutions, hospitals and clinical laboratories. The company’s work spans areas such as drug discovery and development, genetic testing, newborn screening and other diagnostic applications. Its technologies help researchers and healthcare providers analyze biological samples and generate information used in research and patient care.
Recommended Stories
- Five stocks we like better than Revvity
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.
